NEW YORK (GenomeWeb News) — Exact Sciences today said it has extended a licensing agreement for its long-DNA biomarker technology, called DIA, with NorDiag. 
 
Under the non-exclusive license, NorDiag will use the technology, which is designed to identify abnormal apoptosis at the molecular level, in its colorectal cancer-screening tests in Europe, Japan, and Australia.
 
The license also gives NorDiag the right to use the DIA marker to develop an in vitro diagnostic test kit.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.